As NPM1 mutation is associated with heightened HOX/MEIS1 signature[32], the possible role of menin inhibitor merits further investigation and has been shown to enhance anti-AML efficacy of Venetoclax in NPM1-mutant AML models[86]. The gene discussed is MEIS1; the disease is acute myeloid leukemia.